Cancer Supportive Care Drugs Market Forecasts to 2030 – Global Analysis By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Other Cancer Types), Supportive Care Type, Drug Type, Mode of Administration, Distribution Channel a

Cancer Supportive Care Drugs Market Forecasts to 2030 – Global Analysis By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Other Cancer Types), Supportive Care Type, Drug Type, Mode of Administration, Distribution Channel and By Geography

According to Stratistics MRC, the Global Cancer Supportive Care Drugs Market is accounted for $21.46 billion in 2023 and is expected to reach $26.57 billion by 2030 growing at a CAGR of 2.4% during the forecast period. Cancer supportive care drugs are medications designed to manage the symptoms and side effects of cancer treatment, aiming to improve patients' quality of life. These drugs target various issues such as pain, nausea, fatigue, and immune suppression caused by chemotherapy, radiation therapy, or other cancer treatments. They include analgesics, antiemetics, hematopoietic growth factors, and anti-inflammatory agents. These drugs also assist in maintaining treatment adherence by reducing discomfort and enhancing overall well-being.

According to the SEER Database of the U.S. National Cancer Institute, 2020, in the next twenty years, there will likely be 28.4 million new instances of cancer.

Market Dynamics:

Driver:

Rising prevalence of cancer globally

With an increasing number of individuals diagnosed with cancer, there is a higher demand for supportive care drugs to manage symptoms and side effects associated with cancer treatments. This increased demand stems from the necessity to alleviate pain, nausea, fatigue, and other treatment-related complications, enhancing patients' quality of life. Consequently, pharmaceutical companies are motivated to develop and innovate supportive care drugs, driving market expansion to meet the growing healthcare needs of cancer patients worldwide.

Restraint:

Side effects and toxicity

Side effects of cancer supportive care drugs can include nausea, vomiting, fatigue, anaemia, neuropathy, and immunosuppression. Additionally, some drugs may pose risks of toxicity to organs such as the liver or kidneys. These side effects and toxicities can lead to treatment interruptions, dose reductions, or discontinuation, affecting patient adherence and treatment outcomes. Moreover, concerns about adverse effects may deter healthcare providers from prescribing certain drugs, impacting market demand.

Opportunity:

Expansion of palliative care services

Palliative care integration underscores the importance of managing pain, nausea, and other side effects, prompting the development and adoption of supportive care drugs. Expansion of palliative care services increases the demand for medications that alleviate symptoms and improve quality of life for cancer patients. This expansion not only enhances patient well-being but also creates a conducive environment for pharmaceutical companies to innovate and introduce new therapies tailored to address the unique needs of individuals undergoing cancer treatment, thereby fueling market growth.

Threat:

Inadequate healthcare infrastructure

Insufficient facilities, trained personnel, and resources lead to delays in diagnosis, treatment initiation, and proper management of cancer-related symptoms. Moreover, poor infrastructure often results in disparities in healthcare delivery, disproportionately affecting underserved populations. Without adequate infrastructure to support comprehensive cancer care, the demand for supportive care drugs remains unmet, hindering market expansion and depriving patients of essential treatments to alleviate symptoms and improve quality of life.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the cancer supportive care drugs market. Delays in cancer screenings, diagnosis, and treatment, alongside disruptions in healthcare services, have affected the demand for supportive care drugs. Additionally, supply chain disruptions and resource reallocation to address the pandemic have further strained market dynamics. Overall, the pandemic has underscored the importance of resilient healthcare systems and highlighted the need for innovative approaches to cancer care delivery.

The prostate cancer segment is expected to be the largest during the forecast period

The prostate cancer segment is estimated to have a lucrative growth. In the realm of cancer supportive care drugs, addressing the challenges of prostate cancer entails a multifaceted approach. Supportive care drugs for prostate cancer aim to mitigate treatment side effects and improve patients' quality of life. Additionally, drugs targeting prostate cancer-specific symptoms and complications, such as urinary issues or erectile dysfunction, may also play a crucial role. The development and availability of these drugs are pivotal in enhancing the holistic care and well-being of prostate cancer patients.

The intravenous drugs segment is expected to have the highest CAGR during the forecast period

The intravenous drugs segment is anticipated to witness the highest CAGR growth during the forecast period. Intravenous drugs play a pivotal role in cancer supportive care by delivering medications directly into the bloodstream, ensuring rapid and efficient absorption. These drugs are crucial for managing chemotherapy-induced side effects such as nausea, vomiting, anaemia, neutropenia, and pain. They offer targeted treatment, allowing for precise dosing and immediate relief, thereby enhancing the quality of life for cancer patients undergoing treatment.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Increasing cancer prevalence, particularly in populous countries like China and India, drives demand for supportive care drugs to manage symptoms and side effects of cancer treatment. Additionally, improving healthcare infrastructure and rising awareness about cancer care contribute to market expansion. Moreover, collaborations between pharmaceutical companies and healthcare organizations, along with government initiatives to enhance cancer care services, further propel the growth of the cancer supportive care drugs market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and strong emphasis on research and development contribute to this growth. Moreover, favourable reimbursement policies and increasing awareness among both patients and healthcare providers drive demand for supportive care drugs. With a focus on improving patient outcomes and quality of life, North America remains a key region for the development and commercialization of cancer supportive care drugs.

Key players in the market

Some of the key players profiled in the Cancer Supportive Care Drugs Market include Amgen Inc., Johnson & Johnson, Pfizer Inc., Novartis International AG, Merck & Co. Inc., Teva Pharmaceutical Industries Limited, F. Hoffmann-La Roche Limited, Bayer AG, Eli Lilly and Company, AstraZeneca PLC, Bristol Myers Squibb, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, AbbVie Inc. and Daiichi Sankyo Company.

Key Developments:

In November 2023, AstraZeneca’s Truqap in combination with Faslodex has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations. Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.

In March 2022, Novartis received approval from the United States Food and Administration (FDA) for Pluvicto, developed for the treatment of adult patients with prostate cancer. The cancer supportive care drug by Novartis is specially designed for cancer patients that already have had other anti-cancer therapies.

Cancer Types Covered:
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Other Cancer Types

Supportive Care Types Covered:
• Chemotherapy-induced Nausea & Vomiting (CINV) Management
• Anaemia Management
• Neutropenia Management
• Bone Metastasis Management
• Pain Management
• Fatigue Management
• Other Supportive Care Types

Drug Types Covered:
• Anti-emetics
• Erythropoiesis-stimulating Agents (ESAs)
• Granulocyte Colony-stimulating Factors (G-CSFs)
• Bisphosphonates
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Other Drug Types

Mode of Administrations Covered:
• Oral Drugs
• Injectable Drugs
• Topical Drugs
• Intravenous Drugs
• Other Mode of Administrations

Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Cancer Treatment Centers
• Other Distribution Channels

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements